US FDA finds quality lapses at Intas Pharma’s Moraiya biotech unit
The FDA has issued a Form 483 with 14 observations relating to deviations from good manufacturing practices to Intas Pharmaceuticals’ biotech facility in Moraiya, Gujarat
Mumbai: The US Food and Drug Administration (FDA) has issued a Form 483 with 14 observations relating to deviations from good manufacturing practices to Intas Pharmaceuticals Ltd’s biotech facility at Moraiya in Gujarat, according to information available on the US drug regulator’s website.
The FDA issues a Form 483 if its investigators spot any condition that in their judgement may constitute a violation of the US Food Drug and Cosmetic (FD&C) Act and related acts.
The US regulator had inspected the unit between 26 April and 10 May. The company manufactures 17 biological products.
The observations made by the FDA include deficient laboratory records, inappropriate controls over computers, insufficient written records of investigations into unexplained discrepancies in batches, lack of proper control processes to validate causes of variability in characteristics of in-process material and drug product, and lack of written procedures to prevent microbiological contamination.
Some other observations were that the quality control unit lacked responsibility to approve all procedures, there were no written procedures describing calibration of instruments, cell banks were not maintained under appropriate storage monitoring conditions and that buildings used in manufacturing, processing, packing or holding drug products were not free of infestation by birds.
“We observed numerous pigeons perching along the walls, dangling overhead wires and ceiling in the packing material storage warehouse…We observed pigeon faeces on the boxes containing the pre-sterilized empty petri plates and dishes,” the FDA said in the Form 483.
An email query sent to Intas Pharma was not answered till the time of publishing this report.
The company’s Matoda facility in Gujarat, which manufactures tablets and injections, is already approved by the FDA.
- Change M&A norms to calculate spectrum dues: Trai
- Cracking India’s bankruptcy code
- RBI’s registry will help solve problem of credit shortage: iSpirt’s Sharad Sharma
- Fintech regulation at an inflection point: Shardul Amarchand’s Shilpa Mankar Ahluwalia
- Voice and AI biggest transformative tech, says EY’s Mahesh Makhija
Editor's Picks »
- Modi slams opposition, refers to Rahul’s ‘unwanted hug’ at Shahjahanpur rally
- Gold price maintains uptrend on global cues, jewellers’ buying
- Sky is Comcast’s final prize as Disney battle approaches endgame
- Donald Trump and the US dollar: Actions speak louder than words
- Jagan Reddy calls Andhra bandh on 24 July over special status
- What ABB India’s performance in June quarter says about capex growth
- Bajaj Finance does well in Q1 even as competition hots up
- Kotak Mahindra Bank: The perils of being priced to perfection
- Higher cane price crushes hopes of sugar mills
- Market optimism before 2019 general election: History may not repeat itself